SIRT3-KO mice displayed excessive lipid accumulation and decreased palmitate oxidation rates in the heart. by Tongshuai Chen (699646)

CII, inhibitor of SphK, decreases both the migration of HPAECs in a scratch assay <i>in vitro</i> and the content of S1P in HPAECs. by Evgeny V. Berdyshev (307465)

BoNT/A (3.5 U/kg) decreases dural extravasation in IoNC-injured rats which is prevented by intraganglionic colchicine. by Boris Filipović (336089)

Acute traumatic stress in combination with re-exposure stress leads to a long-lasting decrease of hippocampal synapsin Ia-b/IIa expression. by Leonie Herrmann (144380)

SFN decreased MMP-2 expression and activity in U87MG and U373MG cells. by Chunliu Li (284115)

“…<p>(A) SFN decreased MMP-2 expression via activated ERK1/2. …”

BoNT/A (3.5 U/kg) decreases IoNC-induced mechanical allodynia which is prevented by intraganglionic colchicine pretreatment. by Boris Filipović (336089)

<i>In vitro</i> cultured <i>Tfrc</i>^{<i>Y20H/Y20H</i>} B cells display impaired activation, proliferation and differentiation, which can be rescued by iron supplementation... by Sarah K. Wideman (17118275)

Dose-dependent inhibition of V-ATPase with Bafilomycin A1 decreases LysoTracker Red fluorescence and increases Lyso-pHluorin fluorescence. by Yarden Golan (5924594)

Decreased 11ß-HSD1 protein level by IGF-I overexpression <i>in vivo</i> and a direct treatment with IGF-I. by Subrata Chowdhury (787208)

Administration of BL-7010 (Polymers A and B) decreased CD3⁺ intraepithelial cells in villi tips of gliadin-sensitized mice. by Justin L. McCarville (432593)

Table_1_Open-Label Placebo Administration Decreases Pain in Elderly Patients With Symptomatic Knee Osteoarthritis – A Randomized Controlled Trial.pdf by Elisabeth Olliges (7857950)

“…OLP treatments were accompanied by the verbal suggestion “to decrease pain” (OLP-pain, n = 20) or “to improve mood” (OLP-mood, n = 21). …”

Annual number of outpatient visits in all eyes. by Yasuyuki Sotani (20114144)

“…<p>Mean visit frequency (mean ± standard deviation) significantly decreased from 11.5 ± 4.3 preoperatively to 8.8 ± 4.1, 5.0 ± 3.4, and 4.4 ± 3.2 visits in the first, second, and third postoperative years, respectively (Kruskal–Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”

Time course of best-corrected visual acuity (BCVA) in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

“…<p>In the recurrence group, BCVA (logMAR ± standard deviation) showed no significant change from baselines (0.37 ± 0.20) to 0.35 ± 0.23, 0.35 ± 0.18, 0.31 ± 0.23, 0.34 ± 0.26, 0.28 ± 0.30, and 0.24 ± 0.23 at 1, 3, 6, 12, 24, and 36 months, respectively (Kruskal–Wallis test, P = 0.45). …”

Relative expression of gene <i>IL-35</i> (<i>EBI3</i>-A, <i>IL12</i>-B) and protein I in HUVECs prestimulated with 25-OHC (10 μg/mL) for four hours of incubation, followed by remov... by Ewelina Woźniak (11402007)

Figure S1 - Docosahexaenoic Acid Decreases Pro-Inflammatory Mediators in an <i>In Vitro</i> Murine Adipocyte Macrophage Co-Culture Model by Anna A. De Boer (510740)

Annual treatment frequencies in all eyes. by Yasuyuki Sotani (20114144)

“…<p>The number of anti-VEGF treatments, STTA, MA-PC, PPV, and total treatments (mean ± SD) significantly decreased from 2.6 ± 1.6, 0.3 ± 0.8, 0.6 ± 0.8, 0.1 ± 0.3, and 3.7 ± 1.7 preoperatively to 0.8 ± 1.9, 0.0 ± 0.2, 0.3 ± 1.0, 0.0, and 1.2 ± 2.2; at year 2 to 0.7 ± 2.0, 0.1 ± 0.6, 0.0 ± 0.2, 0.0 ± 0.2, and 1.0 ± 2.1; and at year 3 to 0.9 ± 2.2, 0.0, 0.2 ± 1.0, 0.0 ± 0.2, and 1.1 ± 3.1 (Kruskal–Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”

Time course of central retinal thickness (CRT) in all eyes. by Yasuyuki Sotani (20114144)

“…<p>Mean CRT (μm ± standard deviation) significantly decreased from 504.7 ± 118.2 μm preoperatively to 302.5 ± 60.5 at 1 month, 307.5 ± 64.4 at 3 months, 286.8 ± 49.0 at 6 months, 305.3 ± 79.5 at 12 months, 288.8 ± 79.1 at 24 months, and 295.2 ± 87.4 at 36 months (Kruskal–Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”

S1 Data - by Francois Kiemde (5369657)

“…Venous blood was collected at scheduled visit: Visit 1 (V1; 16–20 weeks of amenorrhea), Visit 2 (V2; 28 ±1 weeks of pregnancy), Visit 3 (V3; 32 ±1 weeks of pregnancy), Visit4 (V4; delivery) and Visit5 (V5; 6–7 weeks after delivery). …”

Characteristic of study population. by Francois Kiemde (5369657)

“…Venous blood was collected at scheduled visit: Visit 1 (V1; 16–20 weeks of amenorrhea), Visit 2 (V2; 28 ±1 weeks of pregnancy), Visit 3 (V3; 32 ±1 weeks of pregnancy), Visit4 (V4; delivery) and Visit5 (V5; 6–7 weeks after delivery). …”

Annual treatment frequencies in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

“…Mean outpatient visits in the recurrence group decreased from 13.6 ± 3.0 to 11.9 ± 5.0, 8.1 ± 3.9, and 7.8 ± 3.2 at 1, 2, and 3 years postoperatively, respectively (Kruskal-Wallis test, p < 0.001). …”